Cargando…

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study

BACKGROUND: Lemborexant is a dual orexin receptor antagonist approved to treat insomnia in adults in several countries including the USA, Canada, and Japan. AIMS: This study was conducted to investigate effects of lemborexant and alcohol coadministration on postural stability, cognitive performance,...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Ishani, Hall, Nancy, Aluri, Jagadeesh, Filippov, Gleb, Setnik, Beatrice, Dayal, Satish, Reyderman, Larisa, Moline, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150140/
https://www.ncbi.nlm.nih.gov/pubmed/35634694
http://dx.doi.org/10.1177/02698811221080459
_version_ 1784717360506077184
author Landry, Ishani
Hall, Nancy
Aluri, Jagadeesh
Filippov, Gleb
Setnik, Beatrice
Dayal, Satish
Reyderman, Larisa
Moline, Margaret
author_facet Landry, Ishani
Hall, Nancy
Aluri, Jagadeesh
Filippov, Gleb
Setnik, Beatrice
Dayal, Satish
Reyderman, Larisa
Moline, Margaret
author_sort Landry, Ishani
collection PubMed
description BACKGROUND: Lemborexant is a dual orexin receptor antagonist approved to treat insomnia in adults in several countries including the USA, Canada, and Japan. AIMS: This study was conducted to investigate effects of lemborexant and alcohol coadministration on postural stability, cognitive performance, and the pharmacokinetics, safety, and tolerability of lemborexant. METHODS: This was a Phase 1, double-blind, placebo-controlled, four-period crossover study in 32 healthy adults. Individuals were randomized into one of four treatment sequences to receive single doses of placebo, lemborexant 10 mg (LEM10), alcohol (males, 0.7 g/kg; females, 0.6 g/kg), and LEM10 plus alcohol, each separated by a 14-day washout. Postural stability (body sway) was measured by ataxiameter and a cognitive performance assessment battery evaluated four domains of attention and memory. RESULTS: Pharmacodynamic outcomes were analyzed for the 18 participants who completed all four treatments. Change from baseline in body sway showed no significant differences between lemborexant plus alcohol versus alcohol alone. Compared with alcohol alone, coadministration of lemborexant with alcohol showed additive negative effects on cognitive performance domains, corresponding approximately with peak plasma lemborexant concentrations (median = 1.5 h). Cognitive performance was also impaired with lemborexant alone at 0.5 and 2 h in this experimental paradigm with morning dosing. Alcohol increased plasma lemborexant exposure by 70% based on area under the curve to 72 h, and increased peak plasma lemborexant concentrations by 35%. The most commonly reported treatment–emergent adverse event was somnolence. CONCLUSION: Coadministration of lemborexant with alcohol showed additive negative effects on cognitive measures, but not on postural stability, compared with alcohol alone. Lemborexant exposure was increased with alcohol. Lemborexant alone or with alcohol was well tolerated. Patients are advised not to consume alcohol with lemborexant.
format Online
Article
Text
id pubmed-9150140
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91501402022-05-31 Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study Landry, Ishani Hall, Nancy Aluri, Jagadeesh Filippov, Gleb Setnik, Beatrice Dayal, Satish Reyderman, Larisa Moline, Margaret J Psychopharmacol Original Papers BACKGROUND: Lemborexant is a dual orexin receptor antagonist approved to treat insomnia in adults in several countries including the USA, Canada, and Japan. AIMS: This study was conducted to investigate effects of lemborexant and alcohol coadministration on postural stability, cognitive performance, and the pharmacokinetics, safety, and tolerability of lemborexant. METHODS: This was a Phase 1, double-blind, placebo-controlled, four-period crossover study in 32 healthy adults. Individuals were randomized into one of four treatment sequences to receive single doses of placebo, lemborexant 10 mg (LEM10), alcohol (males, 0.7 g/kg; females, 0.6 g/kg), and LEM10 plus alcohol, each separated by a 14-day washout. Postural stability (body sway) was measured by ataxiameter and a cognitive performance assessment battery evaluated four domains of attention and memory. RESULTS: Pharmacodynamic outcomes were analyzed for the 18 participants who completed all four treatments. Change from baseline in body sway showed no significant differences between lemborexant plus alcohol versus alcohol alone. Compared with alcohol alone, coadministration of lemborexant with alcohol showed additive negative effects on cognitive performance domains, corresponding approximately with peak plasma lemborexant concentrations (median = 1.5 h). Cognitive performance was also impaired with lemborexant alone at 0.5 and 2 h in this experimental paradigm with morning dosing. Alcohol increased plasma lemborexant exposure by 70% based on area under the curve to 72 h, and increased peak plasma lemborexant concentrations by 35%. The most commonly reported treatment–emergent adverse event was somnolence. CONCLUSION: Coadministration of lemborexant with alcohol showed additive negative effects on cognitive measures, but not on postural stability, compared with alcohol alone. Lemborexant exposure was increased with alcohol. Lemborexant alone or with alcohol was well tolerated. Patients are advised not to consume alcohol with lemborexant. SAGE Publications 2022-05-28 2022-06 /pmc/articles/PMC9150140/ /pubmed/35634694 http://dx.doi.org/10.1177/02698811221080459 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Papers
Landry, Ishani
Hall, Nancy
Aluri, Jagadeesh
Filippov, Gleb
Setnik, Beatrice
Dayal, Satish
Reyderman, Larisa
Moline, Margaret
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
title Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
title_full Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
title_fullStr Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
title_full_unstemmed Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
title_short Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
title_sort effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: a randomized, placebo-controlled crossover study
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150140/
https://www.ncbi.nlm.nih.gov/pubmed/35634694
http://dx.doi.org/10.1177/02698811221080459
work_keys_str_mv AT landryishani effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT hallnancy effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT alurijagadeesh effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT filippovgleb effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT setnikbeatrice effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT dayalsatish effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT reydermanlarisa effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy
AT molinemargaret effectofalcoholcoadministrationonthepharmacodynamicspharmacokineticsandsafetyoflemborexantarandomizedplacebocontrolledcrossoverstudy